The Company was incorporated and registered in England and Wales on 13 February 2013 as a private limited company and re-registered on 25 November 2014 as a public limited company. The Company’s wholly owned US operating subsidiary, Hemogenyx Pharmaceuticals LLC, is incorporated in the state of Delaware.
Registered Office
6th Floor
60 Gracechurch Street
London
EC3V 0HR
United Kingdom
Company registered in England & Wales, No. 08401609
Articles of Association
The Company’s current Articles of Association are available for download here.
Employee Incentive Plan
The 2021 Employee Incentive Plan approved by the Board of Directors on 27 July 2021 and by the shareholders at the annual general meeting of 30 June 2022 is available for download here.
Prospectuses
The Prospectus for the investment in Hemogenyx Pharmaceuticals by Mint Capital published on 29 January 2021 is available in PDF format to download here. A Supplementary Prospectus was published on 12 My 2021 following publication of the Company’s annual report for 2020 and is available in PDF format to download here.
The Prospectus for Hemogenyx Pharmaceuticals upon admission to the LSE on 5th October 2017 is available in PDF format to download here.
Documents re. the acquisition of Hemogenyx Pharmaceuticals plc by Silver Falcon plc